Astion Pharma Begins Phase IIb Trial of ASF-1057 in Seborrheic Dermatitis

Astion Pharma A/S has started recruiting patients suffering from seborrheic dermatitis in a Phase IIb study with ASF-1057. ASF-1057 is a potent anti-inflammatory product candidate, for which human proof of concept has already been established. Seborrheic dermatitis affects 3-5% of the population.

This trial is the first in a series of 3 clinical studies to evaluate the effect of ASF-1057 in various doses and formulations. In total 264 patients will be enrolled in these 3 trials.

The study is a double blind, placebo controlled trial. It is being conducted at a clinical centre in Lyon, France. 104 patients suffering from moderate to severe seborrheic dermatitis will be treated once a day for three weeks with three different treatment doses of ASF-1057 or placebo. Additional studies with a similar design will be initiated in Paris and the UK later on.

ASF-1057 has a unique pharmacodynamic profile inhibiting multiple inflammatory processes involved in seborrheic dermatitis. ASF-1057 is formulated as a moisturizing cream for application to the face and chest.

For further information please contact:

Lars Smedegaard Andersen,

EVP Commercial Affairs

Tel: +45 41 12 85 51

Email: lsa@astion.com

Or visit: www.astion.com